Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05181592 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Study acronym: LUSPLUS
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2024 to Oct 31, 2026 Trial status: Recruiting to Active, Not Recruiting · Study sites: 17 to 13 · Completion date: Jun 30, 2025 to Feb 28, 2027v4 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 17 to 13
    • Completion date: Jun 30, 2025 to Feb 28, 2027
  2. Study sites: 5 to 17v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)
Trial Details
NCT Number NCT05181592
Lead Sponsor GWT-TUD GmbH
Collaborators: Celgene
Conditions Myelodysplastic Syndromes
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov